Executive Summary: Electronic health record and health IT software companies are typically valued less like traditional service businesses and more like recurring revenue software platforms. Buyers focus on annual recurring revenue (ARR), net revenue retention (NRR), implementation stickiness, and switching costs because these factors indicate how durable future cash flow will be. For Atlanta business […]
Executive Summary: AI-powered diagnostics companies are valued on more than current revenue. Buyers and investors place premium value on FDA clearance, the strength of clinical validation, recurring licensing revenue, integration with health systems, and evidence that the product can scale without a matching increase in operating costs. For Atlanta business owners in healthcare technology, medtech, […]
Executive Summary: Revenue cycle management (RCM) software companies are often valued differently from traditional software businesses because their revenue is tied to provider workflow, claim throughput, and retention economics rather than simple seat counts. For buyers and investors, the most important questions are how much revenue each provider generates, how efficiently claims are accepted and […]
Executive Summary: Valuing a telehealth platform requires more than applying a revenue multiple to fast growth. Buyers and investors focus on patient visit volume, revenue per visit, payer contract penetration, retention, and the degree to which post-pandemic utilization has normalized. A credible valuation must show whether the platform’s economics are supported by durable demand, recurring […]
Executive Summary: Healthtech companies are valued by combining recurring revenue quality, user or patient engagement, clinical evidence, and regulatory status. For digital health businesses, valuation is rarely driven by revenue alone. Buyers and investors also examine ARR growth, retention, gross margin, clinical outcomes, path to reimbursement, and FDA or other regulatory clearance. A company with […]
InsurTech valuations are driven by a blend of traditional insurance underwriting economics and software-style growth metrics. For Atlanta business owners, investors, and advisors, the key question is not simply whether an InsurTech company is growing, but whether its growth is producing durable, profitable, and scalable revenue. Metrics such as loss ratio, combined ratio, premium growth, […]
Buy-now-pay-later, or BNPL, has moved from a high-growth fintech story to a more disciplined valuation conversation. For Atlanta business owners, investors, and advisors, the question is no longer whether BNPL can scale, but whether its growth is producing durable economics. In today’s market, valuation depends heavily on gross merchandise value (GMV), merchant fee rate, default […]
Executive Summary: Neobank valuation is different from the way investors value traditional banks. Instead of focusing primarily on price-to-book multiples, buyers and investors assess digital bank quality through deposits per user, customer acquisition cost, revenue per account, net revenue retention, churn, and the path to profitability. For Atlanta business owners, especially fintech founders and financial […]
Executive Summary: Valuing a payment processing company requires a close look at the economics that actually drive cash flow, including total payment volume (TPV), take rate, gross margin, and churn. Buyers and investors use these metrics to determine whether a processor is a high-quality, scalable payments platform or a lower-margin infrastructure business with limited pricing […]
Executive Summary: Fintech companies are valued differently from traditional businesses because investors look beyond current earnings and focus on revenue quality, product scalability, regulatory durability, and long-term operating leverage. In payments, lending, and neobanking, valuation often hinges on revenue multiples, growth rates, customer retention, gross margin profile, and the strength of a company’s compliance or […]
- 1
- 2